Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   41470   clinical trials with a EudraCT protocol, of which   6815   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine (ST261) Modified Release Tablets in Patients Affected by Mild Ulcerative Colitis under Oral Stable Treatment.

    Summary
    EudraCT number
    2011-004770-28
    Trial protocol
    ES   HU   LV   DE   LT   AT   PL  
    Global end of trial date
    13 Aug 2013

    Results information
    Results version number
    v1(current)
    This version publication date
    09 Aug 2020
    First version publication date
    09 Aug 2020
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    ST261-DM-11-006
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Alfasigma S.p.A
    Sponsor organisation address
    Via Ragazzi del '99, 5, Bologna, Italy,
    Public contact
    Serena Principe, Alfasigma S.p.A, serena.principe@alfasigma.com
    Scientific contact
    Giovanni Valentini, Alfasigma S.p.A, giovanni.valentini@alfasigma.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Interim
    Date of interim/final analysis
    10 Oct 2013
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    13 Aug 2013
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of this study was to compare the two treatment groups (ST 261 modified release tablets 1g/die vs. placebo) with respect to the proportion of patients with disease remission at the end of the 8 weeks of treatment. Evaluation of safety and tolerability of ST 261 were also primary objectives of the study.
    Protection of trial subjects
    The study was conducted in compliance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline for Good Clinical Practice (GCP) and the applicable national regulations so as to assure that the rights, safety, and wellbeing of the participating study patients were protected consistent with the ethical principles that have their origin in the Declaration of Helsinki.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    21 Jun 2012
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Efficacy, Safety
    Long term follow-up duration
    1 Months
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Poland: 64
    Country: Number of subjects enrolled
    Spain: 16
    Country: Number of subjects enrolled
    Austria: 1
    Country: Number of subjects enrolled
    France: 16
    Country: Number of subjects enrolled
    Germany: 12
    Country: Number of subjects enrolled
    Hungary: 11
    Country: Number of subjects enrolled
    Latvia: 23
    Country: Number of subjects enrolled
    Lithuania: 7
    Worldwide total number of subjects
    150
    EEA total number of subjects
    150
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    143
    From 65 to 84 years
    7
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study was conducted in 55 sites in Austria (3 sites), France (9 sites), Germany (11 sites), Hungary (8 sites), Latvia (4 sites), Lithuania (4 sites), Poland (9 sites) and Spain (7 sites).

    Pre-assignment
    Screening details
    The study consisted of a screening period of up to 2 weeks. Patients with a diagnosis of active mild ulcerative colitis, under stable oral therapy, were screened for entry in the study.

    Pre-assignment period milestones
    Number of subjects started
    150
    Number of subjects completed
    150

    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    ST 261
    Arm description
    Patients randomized to this arm of the study were treated with ST 261 modified release tablets.
    Arm type
    Experimental

    Investigational medicinal product name
    ST 261 modified release tablets
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Modified-release tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Patients randomized to this arm of the study were treated with ST 261 modified release tablets administered orally in one 0.5 g tablet twice a day (before breakfast and before dinner) for 8 weeks.

    Arm title
    Placebo
    Arm description
    Patients randomized to this arm of the study were treated with placebo.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Modified-release tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Patients randomized to this arm of the study were treated with placebo administered orally in one tablet twice a day (before breakfast and before dinner) for 8 weeks.

    Number of subjects in period 1
    ST 261 Placebo
    Started
    76
    74
    Completed
    62
    60
    Not completed
    14
    14
         Sponsor's decision
    4
    -
         Study termination
    3
    3
         Lack of efficacy
    1
    -
         Withdrew from follow-up period
    -
    2
         Withdrawn by Sponsor
    -
    2
         Adverse event, non-fatal
    -
    1
         Consent withdrawn by subject
    4
    5
         Patient's decision
    1
    1
         Lost to follow-up
    1
    -

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    ST 261
    Reporting group description
    Patients randomized to this arm of the study were treated with ST 261 modified release tablets.

    Reporting group title
    Placebo
    Reporting group description
    Patients randomized to this arm of the study were treated with placebo.

    Reporting group values
    ST 261 Placebo Total
    Number of subjects
    76 74 150
    Age categorical
    Units: Subjects
        In utero
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
        Newborns (0-27 days)
    0
        Infants and toddlers (28 days-23 months)
    0
        Children (2-11 years)
    0
        Adolescents (12-17 years)
    0
        Adults (18-64 years)
    0
        From 65-84 years
    0
        85 years and over
    0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    43.0 ± 14.08 45.1 ± 12.38 -
    Gender categorical
    Units: Subjects
        Female
    32 35 67
        Male
    44 39 83
    Subject analysis sets

    Subject analysis set title
    ITT/Safety population Arm ST261
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    Intention-to-treat

    Subject analysis set title
    ITT/Safety population Arm Placebo
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    Intentio-to-treat

    Subject analysis sets values
    ITT/Safety population Arm ST261 ITT/Safety population Arm Placebo
    Number of subjects
    76
    74
    Age categorical
    Units: Subjects
        In utero
        Preterm newborn infants (gestational age < 37 wks)
        Newborns (0-27 days)
        Infants and toddlers (28 days-23 months)
        Children (2-11 years)
        Adolescents (12-17 years)
        Adults (18-64 years)
        From 65-84 years
        85 years and over
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    43.0 ± 14.08
    45.1 ± 12.38
    Gender categorical
    Units: Subjects
        Female
    32
    35
        Male
    44
    39

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    ST 261
    Reporting group description
    Patients randomized to this arm of the study were treated with ST 261 modified release tablets.

    Reporting group title
    Placebo
    Reporting group description
    Patients randomized to this arm of the study were treated with placebo.

    Subject analysis set title
    ITT/Safety population Arm ST261
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    Intention-to-treat

    Subject analysis set title
    ITT/Safety population Arm Placebo
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    Intentio-to-treat

    Primary: Clinical/endoscopic remission

    Close Top of page
    End point title
    Clinical/endoscopic remission
    End point description
    The primary endpoint was clinical/endoscopic remission, defined as a Disease Activity Index (DAI) ≤ 2 with rectal bleeding sub-score = 0 and no other individual sub-score > 1, at the end of the 8 weeks treatment period/early termination. DAI has four sub-scales (stool frequency, rectal bleeding, mucosal appearance and physician's overall assessment of the disease severity) scored using four levels (0, 1, 2, 3). The DAI was calculated by summing the four sub-scores.
    End point type
    Primary
    End point timeframe
    8 weeks
    End point values
    ITT/Safety population Arm ST261 ITT/Safety population Arm Placebo
    Number of subjects analysed
    76
    74
    Units: Subjects
    11
    22
    Statistical analysis title
    Conditional Power
    Statistical analysis description
    The Conditional Power is the probability, given the data observed at the information time t (0 < t < 1) of the interim analysis, that at the end of the 8 weeks period, the two-sided test verifying that the null hypothesis H0 versus the alternative hypothesis H1 is statistically significant at the level α (0.05 for the present studies). Unknown parameters were estimated with the observed data and under the H0 model. The Conditional Power threshold was estimated as 0.25.
    Comparison groups
    ITT/Safety population Arm ST261 v ITT/Safety population Arm Placebo
    Number of subjects included in analysis
    150
    Analysis specification
    Pre-specified
    Analysis type
    other
    P-value
    ≤ 0.25 [1]
    Method
    Conditional Power
    Confidence interval
    Notes
    [1] - Here the Conditional Power threshold is reported (see Analysis description)

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    12 weeks
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    14.1
    Reporting groups
    Reporting group title
    ST 261
    Reporting group description
    Patients randomized to this arm of the study were treated with ST 261 modified release tablets.

    Reporting group title
    Placebo
    Reporting group description
    Patients randomized to this arm of the study were treated with placebo.

    Serious adverse events
    ST 261 Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    ST 261 Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    14 / 76 (18.42%)
    21 / 74 (28.38%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    1 / 76 (1.32%)
    1 / 74 (1.35%)
         occurrences all number
    1
    1
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Fibroadenoma of breast
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    General disorders and administration site conditions
    Haemoglobin Decreased
         subjects affected / exposed
    2 / 76 (2.63%)
    0 / 74 (0.00%)
         occurrences all number
    2
    0
    Pyrexia
         subjects affected / exposed
    1 / 76 (1.32%)
    2 / 74 (2.70%)
         occurrences all number
    1
    2
    Psychiatric disorders
    Depression
         subjects affected / exposed
    1 / 76 (1.32%)
    0 / 74 (0.00%)
         occurrences all number
    1
    0
    Reproductive system and breast disorders
    Breast discomfort
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    Endometriosis
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    Galactorrhoea
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    Injury, poisoning and procedural complications
    Procedural Pain
         subjects affected / exposed
    1 / 76 (1.32%)
    0 / 74 (0.00%)
         occurrences all number
    1
    0
    Investigations
    Haemoglobin Decreased
         subjects affected / exposed
    2 / 76 (2.63%)
    0 / 74 (0.00%)
         occurrences all number
    2
    0
    Body Temperature Increased
         subjects affected / exposed
    1 / 76 (1.32%)
    0 / 74 (0.00%)
         occurrences all number
    1
    0
    Eosinophil Count Increased
         subjects affected / exposed
    1 / 76 (1.32%)
    0 / 74 (0.00%)
         occurrences all number
    1
    0
    Alanine Aminotransferase Abnormal
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    Aspartate Aminotransferase Abnormal
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    Blood alkaline phosphatase abnormal
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    C-Reactive Protein Increased
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    Electrocardiogram T wave abnormal
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    Gamma-Glutamyltransferase Abnormal
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    1 / 76 (1.32%)
    2 / 74 (2.70%)
         occurrences all number
    1
    2
    Productive Cough
         subjects affected / exposed
    1 / 76 (1.32%)
    0 / 74 (0.00%)
         occurrences all number
    1
    0
    Rhinorrhoea
         subjects affected / exposed
    1 / 76 (1.32%)
    0 / 74 (0.00%)
         occurrences all number
    1
    0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    1 / 76 (1.32%)
    0 / 74 (0.00%)
         occurrences all number
    1
    0
    Nervous system disorders
    Syncope
         subjects affected / exposed
    1 / 76 (1.32%)
    4 / 74 (5.41%)
         occurrences all number
    1
    5
    Dysgeusia
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    Headache
         subjects affected / exposed
    0 / 76 (0.00%)
    2 / 74 (2.70%)
         occurrences all number
    0
    3
    Migraine
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    Eye disorders
    Scleritis
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    Gastrointestinal disorders
    Colitis Ulcerative
         subjects affected / exposed
    2 / 76 (2.63%)
    1 / 74 (1.35%)
         occurrences all number
    2
    1
    Abdominal Pain Upper
         subjects affected / exposed
    2 / 76 (2.63%)
    0 / 74 (0.00%)
         occurrences all number
    2
    0
    Diarrhoea
         subjects affected / exposed
    1 / 76 (1.32%)
    1 / 74 (1.35%)
         occurrences all number
    1
    1
    Flatulence
         subjects affected / exposed
    1 / 76 (1.32%)
    0 / 74 (0.00%)
         occurrences all number
    1
    0
    Nausea
         subjects affected / exposed
    1 / 76 (1.32%)
    0 / 74 (0.00%)
         occurrences all number
    1
    0
    Toothache
         subjects affected / exposed
    1 / 76 (1.32%)
    0 / 74 (0.00%)
         occurrences all number
    1
    0
    Abdominal Distension
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    Abdominal Mass
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    Hyperchlorhydria
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    Skin and subcutaneous tissue disorders
    Acne
         subjects affected / exposed
    1 / 76 (1.32%)
    0 / 74 (0.00%)
         occurrences all number
    1
    0
    Hyperhidrosis
         subjects affected / exposed
    1 / 76 (1.32%)
    0 / 74 (0.00%)
         occurrences all number
    1
    0
    Pruritus
         subjects affected / exposed
    1 / 76 (1.32%)
    1 / 74 (1.35%)
         occurrences all number
    1
    2
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    3 / 76 (3.95%)
    2 / 74 (2.70%)
         occurrences all number
    3
    2
    Back Pain
         subjects affected / exposed
    1 / 76 (1.32%)
    0 / 74 (0.00%)
         occurrences all number
    1
    0
    Muscle Tightness
         subjects affected / exposed
    1 / 76 (1.32%)
    0 / 74 (0.00%)
         occurrences all number
    1
    0
    Metabolism and nutrition disorders
    Increased Appetite
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    1 / 76 (1.32%)
    2 / 74 (2.70%)
         occurrences all number
    1
    2
    Influenza
         subjects affected / exposed
    1 / 76 (1.32%)
    0 / 74 (0.00%)
         occurrences all number
    1
    0
    Nasopharyngitis
         subjects affected / exposed
    1 / 76 (1.32%)
    0 / 74 (0.00%)
         occurrences all number
    1
    0
    Gastroenteritis
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1
    Oral herpes
         subjects affected / exposed
    0 / 76 (0.00%)
    1 / 74 (1.35%)
         occurrences all number
    0
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    15 Feb 2012
    Main changes included the following: -The term “parallel-group” was added to the title of the study. -The name of the Sponsor’s responsible physician was updated. -Expected times for site activation, recruitment and approximate total duration of the study were added to the protocol. -The required previous timeframe for patients to repeat the pancolonoscopy at screening was increased from six to twelve months. This would reduce the number of patients requested to undergo an invasive procedure if already done recently. -An exclusion criterion was added to exclude patients receiving treatment with drugs or products containing carnitine or carnitine derivatives during the three months preceding the screening. -The temperature at which the study medication should be maintained was reduced from 30ºC to 25ºC to be more conservative (according to the stability data) with the drug storage conditions. -Some procedural changes and clarifications of the text were made in response to recommendations from Ethics Committees.
    09 Jul 2012
    Main changes included the following: -Smoking history was added as a screening assessment to better characterize patients. -Due to the fluctuations in symptoms observed in mild patients over short periods of time, it was recommended by the DMB and the Steering Committee that the DAI sub-cores relevant to stool frequency and rectal bleeding be recorded twice during the screening period. -The timeframe of at least four weeks was removed from Inclusion Criterion 3 -Diaphragm and spermicidal agent were removed from Inclusion Criterion 7 as they were not considered to be reliable methods (Pearl Index > 1) and in order to fulfill the criterion of highly effective barrier method. -Patients who had been previously treated with biological agents were excluded from the study without taking any washout period into consideration (Exclusion Criterion 6). -Parasites were added in Exclusion Criterion 7. -Bleeding disorders were clarified in Exclusion Criterion 13: alterations of the coagulation factors or any concurrent other disease possibly causing digestive apparatus bleeding. -The decision to stop study treatment administration due to the use of disallowedmedications was left to the Investigators’ judgment. -The limitation that no more than 150 patients should belong to each study for the interim analysis was changed to 200 patients regardless of their origin. Also, the Independent Statistician was added as being responsible for the interim statistical analysis. In addition, the conditional power threshold was changed from Bt = 0.30 as minimum acceptable value for continuing the trial with no additional evaluations to At = 0.25 threshold under which the trial would be stopped.

    Interruptions (globally)

    Were there any global interruptions to the trial? Yes
    Date
    Interruption
    Restart date
    04 Jul 2013
    The present study was conducted in parallel with the Phase III study 2011-004765-32 . In order to early terminate both of the two studies in case of futility, an interim analysis was planned to be performed by combining the samples (first 25% of the total planned patients for each study) of the two studies. The results of this analysis would lead to one of the following scenarios: close the study for futility, or go ahead with the fixed sample size. No sample upsizing or downsizing was planned. This analysis was carried out as planned when 200 patients in total, regardless of which of the two studies they belonged to, were randomized and had reached the final efficacy evaluation (Week 8 or early termination), with no interruption in patient enrolment. The interim analysis was performed in an unblinded manner in the intention-to-treat (ITT) population by an Independent Reporting Statistician who was completely independent from the blinded study team and was not involved in any other duties relevant to the study. The results were given to the Data Monitoring Board (DMB) to review and provide the relevant recommendations according to pre-specified rules. The DMB reviewed the data summary from both studies dated 01 July 2013. Their conclusion was to stop the studies in accordance with the protocol and DMB Charter. This was on the basis of the conditional power as stated in the protocol. The primary reason for stopping the study was strong evidence of futility. The conditional power was 0.004 (below the 0.25 threshold indicated in the protocol). There were no clinical safety issues and no meaningful safety differences were seen.
    -

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA